STD 50-Year Anniversary Issue Reflections on Navigating the Winding Road From Efficacy to Implementation for HIV Preexposure (PrEP) and Doxycycline PEP (Doxy-PEP)
- PMID: 39150124
- PMCID: PMC11335308
- DOI: 10.1097/OLQ.0000000000002045
STD 50-Year Anniversary Issue Reflections on Navigating the Winding Road From Efficacy to Implementation for HIV Preexposure (PrEP) and Doxycycline PEP (Doxy-PEP)
Conflict of interest statement
Conflict of Interest: None declared. Source of Funding: NIH R01AI143439.
References
-
- Sullivan P, Dubose S, Brisco K, et al. Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012–2021. CROI 2024: Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, USA; 2024.
-
- Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308–17. - PubMed
-
- Molina J-MG, Berçot B, Assoumou L, et al. Doxycycline post-exposure prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2×2 factorial design. Lancet Inf Dis 2024; May 23:S1473–3099. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
